Lee Michael S, Wilentz James R, Makkar Raj R, Singh Varinder, Nero Tom, Swistel Daniel, Belsley Scott J, Simon Claude, Rametta Salvatore, DeRose Joseph
Cardiovascular Intervention Center, Cedars-Sinai Medical Center, 8631 W. Third St., Room 415E, Los Angeles, CA 90048, USA.
J Invasive Cardiol. 2004 Aug;16(8):419-25.
Hybrid revascularization (HR) combines staged percutaneous coronary intervention (PCI) on stenoses in the non-left anterior descending (LAD) territories with minimally invasive direct coronary artery bypass (MIDCAB) using the left internal thoracic artery (LITA) to the LAD. The LITA-to-LAD graft, which has a 5-year patency rate of 95%, is the major determinant of the long-term survival for patients. Thus, HR aims to perform full revascularization without compromising the survival advantage of the LITA-to-LAD graft, while preserving the minimally invasive advantages associated with the percutaneous treatment of symptomatic coronary stenoses. We investigated whether HR was a valid alternative to conventional coronary artery bypass graft surgery in patients with multivessel coronary artery disease. We also present our early experiences with HR using a combined approach of advanced PCI and robotically-assisted MIDCAB.
杂交血运重建术(HR)将非左前降支(LAD)区域狭窄病变的分期经皮冠状动脉介入治疗(PCI)与使用左乳内动脉(LITA)至LAD的微创直接冠状动脉旁路移植术(MIDCAB)相结合。LITA至LAD的移植血管5年通畅率为95%,是患者长期生存的主要决定因素。因此,HR旨在实现完全血运重建,同时不影响LITA至LAD移植血管的生存优势,同时保留与有症状冠状动脉狭窄的经皮治疗相关的微创优势。我们研究了HR是否是多支冠状动脉疾病患者传统冠状动脉旁路移植手术的有效替代方案。我们还介绍了使用先进PCI和机器人辅助MIDCAB联合方法进行HR的早期经验。